Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Butorphanol + fentanyl is a combination of two opioid analgesics used for pain management, particularly in perioperative and anesthesia settings. Butorphanol is a synthetic morphinan derivative with mixed agonist-antagonist activity at opioid receptors, acting as a partial agonist/antagonist at the mu-opioid receptor and as an agonist at the kappa-opioid receptor. Fentanyl is a potent synthetic opioid that acts primarily as a full agonist at the mu-opioid receptor, providing strong analgesic effects. The combination may be used to enhance analgesia while potentially reducing some side effects associated with higher doses of individual opioids. Both drugs act on the central nervous system to modulate pain perception and response[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on butorphanol + fentanyl.